Somewhat Positive News Coverage Somewhat Unlikely to Affect Corvus Pharmaceuticals (CRVS) Share Price

Media stories about Corvus Pharmaceuticals (NASDAQ:CRVS) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corvus Pharmaceuticals earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.8005419361391 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Separately, Zacks Investment Research lowered Corvus Pharmaceuticals from a “buy” rating to a “sell” rating in a research note on Tuesday, September 12th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $20.25.

Shares of Corvus Pharmaceuticals (NASDAQ:CRVS) traded down $0.36 during trading on Monday, hitting $10.85. The company had a trading volume of 19,800 shares, compared to its average volume of 52,825. Corvus Pharmaceuticals has a 1 year low of $8.27 and a 1 year high of $22.14. The stock has a market cap of $228.30, a price-to-earnings ratio of -4.03 and a beta of -1.51.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Thursday, November 2nd. The company reported ($0.62) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.19. equities research analysts anticipate that Corvus Pharmaceuticals will post -2.82 EPS for the current year.

In other news, CEO Richard A. Md Miller acquired 10,000 shares of the stock in a transaction that occurred on Monday, November 20th. The shares were bought at an average cost of $10.79 per share, for a total transaction of $107,900.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 46.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Corvus Pharmaceuticals (CRVS) Share Price” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Insider Buying and Selling by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

What are top analysts saying about Corvus Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corvus Pharmaceuticals and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit